WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) announced today that it is currently focusing on partnership discussions, and thus is postponing its plans for announcing its new product development program, originally scheduled for late in the third quarter of 2007. These discussions primarily cover the Company’s lead product candidate, Imagify™, (perflubutane polymer microspheres) injectable suspension, a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States.
